To investigate the synergy between KCL-HO-1i and chemotherapy in a second model, we utilized subcutaneous MN-MCA1 sarcoma tumors (47), which contain HO-1 expressing LYVE-1+CD206hi TAMs (Figure S3A-C) that reside in the Pv niche (Figure S3C). Here, LYVE1 is linked to sarcoma.